{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:09:21Z","timestamp":1766268561168},"reference-count":32,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2019]]},"DOI":"10.7883\/yoken.jjid.2018.472","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T18:03:11Z","timestamp":1553536991000},"page":"285-291","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Evaluation of a Newly Developed Chemiluminescent Enzyme Immunoassay for Hepatitis C Virus Core Antigen in Japan"],"prefix":"10.7883","volume":"72","author":[{"given":"Takako","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Nagoya City University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Ohike","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Nagoya City University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Ohne","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Nagoya City University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Nagoya City University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Goto","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Nagoya City University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Nagoya City University Hospital"},{"name":"Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mohd HK, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-42.","DOI":"10.1002\/hep.26141"},{"key":"2","unstructured":"2. Lee MH, Yang HI, Yuan Y, et al. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270-80."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Pawlotsky JM, Feld JJ, Zeuzem S, et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87-99.","DOI":"10.1016\/j.jhep.2015.02.006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Seifert LL, Perumpail RB, Ahmed A. Update on hepatitis C: direct-acting antivirals. World J Hepatol. 2015;7:2829-33.","DOI":"10.4254\/wjh.v7.i28.2829"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645-53.","DOI":"10.1016\/S1473-3099(15)70099-X"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21:762-8.","DOI":"10.1111\/jvh.12312"},{"key":"7","unstructured":"7. World Health Organization (WHO). Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection. 2018. p. 41-50."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cohn J, Roberts T, Amorosa V, et al. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment. Curr Opin HIV AIDS. 2015;10:369-73.","DOI":"10.1097\/COH.0000000000000180"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Easterbrook PJ, WHO Guidelines Development Group. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65:S46-S66.","DOI":"10.1016\/j.jhep.2016.08.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nguyen LT, Gray E, O'Leary A, et al. The role of hepatitis C virus core antigen testing in the era of direct acting antiviral therapies: what we can learn from the protease inhibitors. PLoS One. 2016;11:e0163900.","DOI":"10.1371\/journal.pone.0163900"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rockstroh JK, Feld JJ, Chevaliez S, et al. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. J Virol Methods. 2017;245:14-8.","DOI":"10.1016\/j.jviromet.2017.03.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tanaka Y, Takagi K, Fujihara T, et al. High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature. Hepatol Res. 2003;26:261-7.","DOI":"10.1016\/S1386-6346(03)00113-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ottiger C, Gygli N, Huber AR. Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol. 2013;58:535-40.","DOI":"10.1016\/j.jcv.2013.08.028"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Agha S, Tanaka Y, Saudy N, et al. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan. J Med Virol. 2004;73:216-22.","DOI":"10.1002\/jmv.20078"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016;165:345-55.","DOI":"10.7326\/M16-0065"},{"key":"16","unstructured":"16. WHO. Towards the Elimination of Hepatitis B and C by 2030. The draft WHO Global Hepatitis Strategy, 2016\u20132021 and Global Elimination Targets. Available at <http:\/\/www.worldhepatitissummit.org\/docs\/default-source\/default-document-library\/2015\/resources\/towards-elimination-dr-gottfried-hirnschall.pdf?sfvrsn=6>. Accessed November 1, 2018."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cresswell FV, Fisher M, Hughes DJ, et al. Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. Clin Infect Dis. 2015;60:263-6.","DOI":"10.1093\/cid\/ciu782"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Li Cavoli G, Zagarrigo C, Schillaci O, et al. Hepatitis C virus core antigen test in monitoring of dialysis patients. Hepat Res Treat. 2012;2012:832021.","DOI":"10.1155\/2012\/832021"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Aghemo A, Degasperi E, De Nicola S, et al. Quantification of core antigen monitors efficacy of direct-acting antiviral agents in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2016;14:1331-6.","DOI":"10.1016\/j.cgh.2016.03.035"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Loggi E, Cursaro C, Scuteri A, et al. Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol. 2013;56:207-11.","DOI":"10.1016\/j.jcv.2012.11.012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kadkhoda K, Smart G. HCV antigen testing for the diagnosis of hepatitis C infection: a cost-efficient algorithm. Clin Lab. 2014;60:677-80.","DOI":"10.7754\/Clin.Lab.2013.130634"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kotb DN, Esmail MA, Abdelwahab SF, et al. Correlation between hepatitis C viral load and hepatitis C core antigenaemia among Egyptians. East Mediterr Health J. 2017;23:280-6.","DOI":"10.26719\/2017.23.4.280"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Momose H, Matsuoka S, Murayama A, et al. Evaluation of in vitro screening and diagnostic kits for hepatitis C virus infection. J Clin Virol. 2018;105:97-102.","DOI":"10.1016\/j.jcv.2018.06.008"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Saeed M, Suzuki R, Kondo M, et al. Evaluation of hepatitis C virus core antigen assays in detecting recombinant viral antigens of various genotypes. J Clin Microbiol. 2009;47:4141-3.","DOI":"10.1128\/JCM.01437-09"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Murayama A, Sugiyama N, Watashi K, et al. Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol. 2012;50:1943-9.","DOI":"10.1128\/JCM.00487-12"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-94.","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hellard ME, Chou R, Easterbrook P. WHO guidelines on testing for hepatitis B and C - meeting targets for testing. BMC Infect Dis. 2017;17:703.","DOI":"10.1186\/s12879-017-2765-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Chevaliez S, Soulier A, Poiteau L, et al. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol. 2014;61:145-8.","DOI":"10.1016\/j.jcv.2014.05.014"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kamal SM, Kassim S, El Gohary E, et al. The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2015;42:307-18.","DOI":"10.1111\/apt.13261"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Chevaliez S, Feld J, Cheng K, et al. Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. Antivir Ther. 2018;23:211-7.","DOI":"10.3851\/IMP3042"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Mohamed Z, Mbwambo J, Shimakawa Y, et al. Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania. J Int AIDS Soc. 2017;20:21856.","DOI":"10.7448\/IAS.20.1.21856"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Lamoury FMJ, Hajarizadeh B, Soker A, et al. Evaluation of a hepatitis C virus core antigen assay in plasma and dried blood spot samples. J Mol Diagn. 2018;20:621-7.","DOI":"10.1016\/j.jmoldx.2018.05.010"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/72\/5\/72_JJID.2018.472\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T23:36:36Z","timestamp":1569022596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/72\/5\/72_JJID.2018.472\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2018.472","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}